Core Viewpoint - Trinity Biotech plc has provided an update on its trading activities for Q4 2025, highlighting both challenges and strategic advancements in its business operations, particularly in the areas of HIV testing and diabetes management solutions [1]. Trading Update - The company expects Q4 2025 revenue to be between approximately $11.5 million and $12.5 million, a decrease from $15.9 million in Q4 2024, primarily due to disruptions in the global health market for HIV testing and adjustments in manufacturing processes [8]. Business Update - The company is focused on profitable growth and advancing its innovation agenda, including the flagship development of CGM+ [3]. - Key regulatory approvals have been secured, including the outsourcing of production for the Uni-Gold™ HIV rapid test, which is a priority in the Comprehensive Transformation Plan [4]. - The company is experiencing strong demand for its Uni-Gold™ HIV test and expects this segment to contribute significantly to revenue in 2026 [5]. - The transition to outsourced manufacturing aims to reduce fixed costs and mitigate revenue variability, although it may introduce temporary fluctuations in quarterly revenue [6]. - The company is enhancing its diabetes care solutions, having received a Gold Classification from the IFCC for its Premier Hb9210 HbA1c monitoring solution and is expanding its commercial efforts in the US and Brazil [7][10]. Pipeline Developments - The company continues to advance key strategic growth projects, including the development of CGM+, EpiCapture for prostate cancer monitoring, and PrePsia for early pregnancy screening [13].